Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia

English version České info

In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic leukemia.

Vyšlo v časopise: Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia. PLoS Med 13(12): e32767. doi:10.1371/journal.pmed.1002208
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002208

Souhrn

In a Perspective, Pieter Van Vlierberghe and Steven Goossens discuss Meijerink and colleagues' findings on steroid resistance in pediatric T cell acute lymphoblastic leukemia.

Zdroje

1. Durinck K, Goossens S, Peirs S, Wallaert A, Van Loocke W, Matthijssens F, et al. Novel biological insights in T cell acute lymphoblastic leukemia. Exp Hematol. 2015;43(8):625–39. doi: 10.1016/j.exphem.2015.05.017 26123366

2. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541–52. doi: 10.1056/NEJMra1400972 26465987

3. Inaba H, Pui CH. Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol. 2010;11(11):1096–106. doi: 10.1016/S1470-2045(10)70114-5 20947430

4. Li Y, Buijs-Gladdines JG, Canté-Barrett K, Stubbs AP, Vroegindeweij EM, et al. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T Cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study. PLoS Med. 2016;13(12):e1002200. doi: 10.1371/journal.pmed.1002200

5. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008;205(4):751–8. doi: 10.1084/jem.20072182 18362173

6. Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lengline E, et al. Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31(34):4333–42. doi: 10.1200/JCO.2012.48.5292 24166518

7. Aries IM, van den Dungen RE, Koudijs MJ, Cuppen E, Voest E, Molenaar JJ, et al. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance. Haematologica. 2015;100(4):e132–6. doi: 10.3324/haematol.2014.112995 25480501

8. Irving J, Matheson E, Minto L, Blair H, Case M, Halsey C, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. Blood. 2014;124(23):3420–30. doi: 10.1182/blood-2014-04-531871 25253770

9. Jing D, Bhadri VA, Beck D, Thoms JA, Yakob NA, Wong JW, et al. Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells. Blood. 2015;125(2):273–83. doi: 10.1182/blood-2014-05-576470 25336632

10. Bachmann PS, Piazza RG, Janes ME, Wong NC, Davies C, Mogavero A, et al. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. Blood. 2010;116(16):3013–22. doi: 10.1182/blood-2010-05-284968 20647567

11. Wuchter C, Ruppert V, Schrappe M, Dorken B, Ludwig WD, Karawajew L. In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T cell acute lymphoblastic leukemia. Blood. 2002;99(11):4109–15. 12010814

12. Karawajew L, Ruppert V, Wuchter C, Kosser A, Schrappe M, Dorken B, et al. Inhibition of in vitro spontaneous apoptosis by IL-7 correlates with bcl-2 up-regulation, cortical/mature immunophenotype, and better early cytoreduction of childhood T cell acute lymphoblastic leukemia. Blood. 2000;96(1):297–306. 10891465

13. Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738–47. doi: 10.1182/blood-2014-05-574566 25301704

14. Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, et al. Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T cell precursor (ETP) acute lymphoblastic leukemia. Blood. 2015;125(11):1759–67. doi: 10.1182/blood-2014-06-580480 25645356

15. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477–82. doi: 10.1038/nature19830 27760111

16. Hall CP, Reynolds CP, Kang MH. Modulation of Glucocorticoid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235. Clin Cancer Res. 2016;22(3):621–32. doi: 10.1158/1078-0432.CCR-15-0114 26080839